Our latest collaboration with Mammoth Biosciences - using LAMP and CRISPR for the rapid detection of SARS-CoV-2 variants journals.asm.org/doi/full/10.11…

Some of our scientists have been having fun with DALL·E from OpenAI. If our mascot were to work in the lab, which of the following do you think would most accurately represent them? (Respond in the poll below🔽) 🤔🦣🧪🥼 #FridayFeeling #SciArt #Science #dalle

1/ I'm excited to publicly talk about Power (withpower.com) for the first time At Power we believe that clinical trials should be accessible for any patient in need -- not just those with top doctors to help them out

We recently worked with the Chiu laboratory at UCSF to develop a SNP-detecting #CRISPR system for #SARSCoV2 variant surveillance. Learn about our pipeline for developing Cas proteins for this & many other exciting applications in this GenomeWeb article: genomeweb.com/molecular-diag… #COVID19

Hats off to Mammoth Biosciences. Nobody knows better how important CRISPR/Cas9 has been to the gene editing field. And no one knows better than the folks running this Jennifer Doudna startup just how much the field still needs to be developed. endpts.com/the-endpoints-…

#HappyHalloween! Our mascot is still trying to perfect their costume with a little help from OpenAI. Which one is your favorite?

Incredibly excited to welcome Phil (CBO) and Siang (GC) to the Mammoth team! We all share an ambitious vision for the potential of CRISPR and they will further propel us towards delivering on the full promise of this transformative technology.

Excited to present at the 41st Annual J.P. Morgan Healthcare Conference at 4:00 PM PT today! I'll discuss Mammoth's vision and how we're building a long term differentiated biotech.

Please join me and some amazing biotech colleagues for a night of conversation and connection tomorrow (March 21) at IndieBio (IndieBio) (479 Jessie St, SF) to raise money for Boston Children's Hospital. Tickets available at the link (bit.ly/40cso4j) see you there!

We look forward to working with Regeneron to enable all-in-one AAV delivery and unlock the true potential of in vivo gene editing. Read our press release to learn more: mammoth.bio/regeneron-and-… @doudna_lab UC Berkeley

🎉Thrilled to announce our collaboration with Regeneron with a 100MM upfront! We believe that collaborating with Regeneron is a critical step toward maximizing the impact of our technology

Proud to share this collaboration that brings the best of Mammoth Biosciences's ultracompact CRISPR with Regeneron's antibody-directed AAVs. Both are founder-led and science-driven companies with a shared commitment to realize the full therapeutic potential of #CRISPR! 🧬

So excited to be a finalist in the Emerging Innovation category of the California Life Sciences (CLS) #PantheonAwards. We're working to cure diseases through in vivo gene editing with our ultra compact #CRISPR systems, so please support us with your vote! califesciences.org/pantheon-votin…

🚀 Emerging Innovation Award goes to Mammoth Biosciences ! Congrats to the team pushing biotech boundaries! #Pantheon2024

General Proximity (General Proximity) is coming out of stealth. General Proximity is developing a new class of medicines that we believe has the potential to decrease global disease burden, transform human health, and extend lifespan more than any other current therapeutic modality. 🧵

📢Excited to introduce NanoCas -our new mini CRISPR system that can reach tissues previously out of reach! By shrinking CRISPR to 1/3 its normal size, we can now edit genes in muscle, heart & brain that were difficult to access before. Summary & link to paper:

🧬CRISPR proteins shrink, but its potential expands! #NanoCas, featured in Science Magazine, edits NHP muscle via single-AAV delivery – unlocking therapies for hard-to-target diseases. Huge thanks to J Couzin-Frankel for covering our research! science.org/content/articl… #CRISPR #Biotech

Thanks to Science Magazine for covering our preprint on NanoCas!